KRAS and colorectal cancer: In this study, we present a case of colorectal cancer that demonstrated resistance to the encorafenib and cetuximab regimen, attributed to the presence of a KRAS mutation in addition to BRAF. The information obtained from both companion diagnosis and CGP testing proved beneficial for selecting the appropriate drug in the later stages of treatment.